This story originally ran on Nov. 18.

By Tony Fong

Despite a contraction in revenues related to its core technology, sample prep firm Pressure BioSciences this week reported a 19-percent increase in total revenues for the third quarter.

For the three months ended Sept. 30, the South Easton, Mass.-based company posted receipts of $317, 427, up from $265,662. Net loss for the quarter shrank 31 percent to $753,449, or $0.35 per share, from $1.1 million, or $0.50 per share, a year ago.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.